FORM 4
--------

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)											
1. Name and Address of Reporting Person- Leon Alfonzo	2. Issuer Name and Global Medical			<b>e</b> .	ol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) 2 BETHESDA METRO CENTER,	3. Date of Earliest Transaction (Month/Day/Year) 03/05/2019						X_Officer (give title below) Other (specify below) Chief Investment Officer				
(Street) BETHESDA, MD 20814	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State)	(Zip)	Т	able I - No	n-De	rivative S	ecuritie	s Acqu	ired, Disposed of, or Beneficially Owned			
1.Title of Security	2. Transaction	2A. Deemed	3. Transact	tion	4. Securi	ties Acqu	uired	5. Amount of Securities Beneficially	6.	7. Nature	
(Instr. 3) Date		Execution Date, if	Code		(A) or Disposed of (D)		of (D)	Owned Following Reported	Ownership	of Indirect	
	(Month/Day/Year)	any	(Instr. 8)		(Instr. 3,	4 and 5)		Transaction(s)	Form:	Beneficial	
		(Month/Day/Year)	Code	v	Amount	(A) or (D)	Price	(Instr. 3 and 4)	Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information SEC 1474 (9-02) contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

( <i>e.g.</i> , puts, calls, warrants, options, convertible securities)															
Security	Conversion	3. Transaction Date (Month/Day/Year)		Code	tion )	5. Numb of Deriva Securitie Acquired or Dispo of (D) (Instr. 3, and 5)	ative s l (A) sed	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	Securities Beneficially Owned Following Reported Transaction(s)		Beneficial
				Code	V	(A)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
LTIP Unit (Right to Buy) (1)	<u>(2)</u>	03/05/2019 <sup>(3)</sup>		А		12,765 ( <u>3</u> )		(2)	(2)	Common Stock	12,765	\$ 0	62,861	D	
LTIP Unit (Right to Buy) (4)	<u>(2)</u>	03/05/2019 <sup>(4)</sup>		А		8,342 ( <u>4</u> )		(2)	(2)	Common Stock	8,342	\$ 0	71,203	D	
LTIP Unit (Right to Buy) (5)	<u>(2)</u>	03/05/2019 <sup>(5)</sup>		А		3,125 (5)		(2)	(2)	Common Stock	3,125	\$ 0	74,328	D	

# **Reporting Owners**

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Leon Alfonzo 2 BETHESDA METRO CENTER, SUITE 440 BETHESDA, MD 20814			Chief Investment Officer					

## Signatures

\*\*Signature of Reporting Person

03/07/2019 Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Represents units of limited partnership interest ("LTIP Units") in Global Medical REIT L.P. (the "OP"), the operating partnership of the Issuer. The Issuer's Board of Directors
  (1) determined on March 5, 2019 that 50% of the LTIP Units vested and became nonforfeitable as a result of meeting certain market based performance criteria as of December 31, 2018 and 50% of the LTIP Units will vest on March 5, 2020, pursuant to the grant award agreement stipulations. The performance-based LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan and have no expiration date.
- (2) As described in the OP's partnership agreement, vested LTIP Units may be exchanged at any time after the first anniversary of the grant date (so long as capital parity has been achieved) for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date.
- (3) Awarded pursuant to an LTIP Unit performance-based vesting agreement, the form of which was filed as Exhibit 99.3 to the Issuer's Current Report on Form 8-K filed on April 12, 2018.
- (4) LTIP Units vest in equal one-third installments on March 5 of 2020, 2021 and 2022. The LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan and have no expiration date.
- (5) 50% of the LTIP Units vested at issuance and the remaining will vest on March 5, 2020 pursuant to the grant award agreement stipulations.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.